What If a protein variant between Covid19/HIV has been incubated in all of us as a sleeper protein/virus that will be activated by a process
unknown.
Then Covid/Corona that is a mutational virus of 5 or maybe 6 base origins.
So HIV is a retro virus that can not be cured only made undetectable in the blood basically a person's Viral load ??
Do we then, have to urgently find inhibitors, for both Corona mutations and HIV, its strange that HIV treatment is sometimes called
combination
therapy or ART Antiretroviral therapy.
I wonder was this trailed in Africa? and then amongst other communities in the last 30 years or so before being refined and released on us all ????
Keep an eye out for references to Karposis Sarcoma in relation to covid ???
Ranitidine keeps on popping up WHY
A 24-year-old, Chinese HIV-infected patient with a 2-year treatment history with tenofovir, lamivudine and efavirenz (CD4 cell count and HIV-RNA
levels unreported), had a non-severe course of COVID-19 Lopinavir/ritonavir had been added to the antiretroviral regimen after COVID-19 diagnosis.
www.ncbi.nlm.nih.gov...
A further Chinese patient living with HIV had 34 CD4 cells/μL and a prolonged course of COVID-19 (12). An additional HIV-infected patient with fever,
muscle aches and right lower lobe pneumonia at a chest CT scan was reported by Chinese authors from Shenzhen (13). However, SARS-CoV-2 RNA was
persistently negative on different specimen samples at various times during the course of his illness (13), and we cannot therefore be sure that this
patient was SARS-CoV-2-coinfected.
Three HIV-coinfected cases have been reported from Italy (16). A 62-year-old man with undetectable viral load and 441 CD4 cells/μL required
mechanical ventilation and improved; a 63-year-old man with undetectable HIV-RNA and 743 CD4 cells/μL and a 57-year-old woman (HIV-RNA and CD4 cell
count not reported) had an uneventful course (16). Interestingly, prior to getting SARS-CoV-2 all the three patients were on darunavir-based
antiretroviral therapy, and pharmacokinetic data showed good compliance, suggesting that darunavir, at least at the currently employed 800 mg dosage,
does not prevent SARS-CoV-2 infection HIV-infected individuals (16). It must be stressed that Janssen reported on March 18, 2020, that darunavir is
not effective against SARS-CoV-2 due to low affinity to coronavirus protease.
www.ncbi.nlm.nih.gov...
Okay...
The co-existence of the two epidemics of HIV and SARS-CoV-2 could be particularly deleterious for people living with HIV not only in low and
middle-income countries but also in high income countries. Widespread lockdowns, enforced in an attempt to curb the spread of SARS-CoV-2 infection,
lead to patients' job losses, difficulties in reaching the clinics where anti-HIV drugs are distributed, and problems in drug supplies to the clinics.
Funds needed to step up the response to the new pandemic could reduce those assigned to the fight against HIV infection/AIDS and TB, and vulnerable
HIV-infected populations (drug users, sex workers, poor patients living in urban slums or in rural areas, prisoners) would particularly suffer from
this. Any efforts will have to be made to prevent or limit the above problems. In any case, it will be extremely important to describe the features of
SARS-CoV-2 infection and the evolution of COVID-19 in HIV-infected patients, including whether HIV-infected people develop sufficient level of
anti-SARS-CoV-2 antibodies, and their persistence over time. Even in this difficult situation, clinical and research centres, including those in
Africa, will have to strive to clarify the numerous aspects of this unprecedented coinfection for the benefit of all HIV-infected patients
worldwide.
www.ncbi.nlm.nih.gov...
Pharmacology letter Accelerated communication
The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: Identification of a new class of antiviral
agents
Author links open overlay panelAldar S.BourinbaiarEric C.Fruhstorfer
doi.org...(96)00553-XGet rights and content
Abstract
The suppression of human immunodeficiency virus (HIV) replication by histamine type 2 (H2) receptor antagonists, cimetidine, ranitidine, and
famotidine was examined in vitro. The 50% reduction (IC50) in p24 antigen expression caused by the anti-ulcer agent, cimetidine, was observed at 26.8
nM with IC100 at 10 μM. Unlike azidothymidine — a reverse transcriptase inhibitor — cimetidine blocked HIV infection without affecting cell
growth, as no cytotoxicity was observed even at the highest 1 mM dose. Ranitidine and famotidine were less potent than cimetidine. H1 antagonists,
cyproheptadine and diphenhydramine, had no effect on HIV replication. Although the activity of cimetidine was observed at concentrations attainable by
oral administration, the mechanism of anti-HIV action is unknown. This is the first report on antiretroviral action of H2 blockers. Further studies
are warranted to establish the potential of a new class of anti-HIV agents with immunomodulating properties.
pubmed.ncbi.nlm.nih.gov...
Ranitidine keeps on popping up WHY
In UK Ranitidine was pulled in early November LITERALLY OVERNIGHT ??
Stomach Alkaline immune system
edit on 25-9-2020 by Fingle because: (no reason given)
edit on 25-9-2020 by Fingle because: (no reason given)
I could be a Genius, mentally ill, Drunk, or ...on Drugs even all four
edit on 25-9-2020 by Fingle because: (no reason
given)